JP2005526821A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005526821A5 JP2005526821A5 JP2003581783A JP2003581783A JP2005526821A5 JP 2005526821 A5 JP2005526821 A5 JP 2005526821A5 JP 2003581783 A JP2003581783 A JP 2003581783A JP 2003581783 A JP2003581783 A JP 2003581783A JP 2005526821 A5 JP2005526821 A5 JP 2005526821A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- treatment
- drug
- yanovich
- doxorubicin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cells Anatomy 0.000 description 7
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drugs Drugs 0.000 description 3
- UCSJYZPVAKXKNQ-HZYVHMACSA-N 1-[(1S,2R,3R,4S,5R,6R)-3-carbamimidamido-6-{[(2R,3R,4R,5S)-3-{[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy}-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy}-2,4,5-trihydroxycyclohexyl]guanidine Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 229960004679 Doxorubicin Drugs 0.000 description 2
- 206010024324 Leukaemias Diseases 0.000 description 2
- 210000001700 Mitochondrial Membranes Anatomy 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M Sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002609 media Substances 0.000 description 2
- 230000002062 proliferating Effects 0.000 description 2
- 229960002743 Glutamine Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 229940049954 Penicillin Drugs 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000007759 RPMI Media 1640 Substances 0.000 description 1
- 210000002966 Serum Anatomy 0.000 description 1
- 229940054269 Sodium Pyruvate Drugs 0.000 description 1
- 229960005322 Streptomycin Drugs 0.000 description 1
- 229940029983 VITAMINS Drugs 0.000 description 1
- 241000863480 Vinca Species 0.000 description 1
- 229940021016 Vitamin IV solution additives Drugs 0.000 description 1
- 229930013930 alkaloids Natural products 0.000 description 1
- 239000003817 anthracycline antibiotic agent Substances 0.000 description 1
- 229960000626 benzylpenicillin Drugs 0.000 description 1
- 230000001086 cytosolic Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001605 fetal Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamins Natural products 0.000 description 1
Description
さらに、本発明は、増殖性疾患の処置のための、そして増殖性疾患の処置用医薬の製造のための「本発明の組合せ剤」の使用に関する。
実施例１：
細胞：Ｋ５６２ヒト白血病細胞を、ＡＴＣＣ、Ｒｏｃｋｖｉｌｌｅ、ＭＤから購入し、そしてピルビン酸ナトリウム、ＭＥＭ必須ビタミン、Ｌ−グルタミン、ペニシリン、ストレプトマイシン、および１０％熱不活性化ウシ胎児血清（Ｈｙｃｌｏｎｅ、Ｌｏｇａｎ、ＵＴ）を補ったＲＰＭＩ １６４０培地中で培養する。薬物耐性Ｋ５６２細胞（Ｋ５６２Ｒ）を、ヤノビッチら（Yanovich et al）において過去に記載されたように濃度漸増ドキソルビシン中で継代培養することにより親株から得る。Ｋ５６２ヒト白血病細胞株のドキソルビシン−耐性変異種（Ｋ５６２Ｒ）は、他のアントラサイクリン系抗生物質およびビンカアルカロイドとの交差耐性を示す。Ｋ５６２Ｒ細胞は、他の多剤耐性細胞株とよく似た表現型を有する（Yanovich et al., 1989, Cancer Res. 49, 4499-4503）。それらは、すべての実験手順の前に薬物の入っていない培地中で培養される。
Ｓ−１００フラクションの製造：細胞を、薬物処置の後に回収し、そして細胞質内Ｓ−１００フラクションを、Yu et al., Mol. Pharmacol. 2001, 60, 143-53において記載されたような超遠心分離により単離する。
細胞：Ｋ５６２ヒト白血病細胞を、ＡＴＣＣ、Ｒｏｃｋｖｉｌｌｅ、ＭＤから購入し、そしてピルビン酸ナトリウム、ＭＥＭ必須ビタミン、Ｌ−グルタミン、ペニシリン、ストレプトマイシン、および１０％熱不活性化ウシ胎児血清（Ｈｙｃｌｏｎｅ、Ｌｏｇａｎ、ＵＴ）を補ったＲＰＭＩ １６４０培地中で培養する。薬物耐性Ｋ５６２細胞（Ｋ５６２Ｒ）を、ヤノビッチら（Yanovich et al）において過去に記載されたように濃度漸増ドキソルビシン中で継代培養することにより親株から得る。Ｋ５６２ヒト白血病細胞株のドキソルビシン−耐性変異種（Ｋ５６２Ｒ）は、他のアントラサイクリン系抗生物質およびビンカアルカロイドとの交差耐性を示す。Ｋ５６２Ｒ細胞は、他の多剤耐性細胞株とよく似た表現型を有する（Yanovich et al., 1989, Cancer Res. 49, 4499-4503）。それらは、すべての実験手順の前に薬物の入っていない培地中で培養される。
Ｓ−１００フラクションの製造：細胞を、薬物処置の後に回収し、そして細胞質内Ｓ−１００フラクションを、Yu et al., Mol. Pharmacol. 2001, 60, 143-53において記載されたような超遠心分離により単離する。
ミトコンドリア膜ポテンシャルの測定（ΔΨｍ）：ミトコンドリア膜ポテンシャルを、ＦＡＣＳｃａｎフロー・サイトメーターおよびＣｅｌｌＱｕｅｓｔソフトウェア（Becton Dickinson, Immunocytometry Systems, San Jose, CA）を用いて、Wang Z. et al., 1999 Cancer Res. 59, 1259-67において過去に記載されたように３,３−ジヘキシルオキサカルボシアニン ヨーダイド（ＤｉＯＣ６）の取り込みを測定することによりモニターする。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37133002P | 2002-04-10 | 2002-04-10 | |
| PCT/IB2003/001418 WO2003084543A1 (en) | 2002-04-10 | 2003-04-04 | Combination of glivec(sti571) with a cyclin-dependent kinase inhibitor, especially flavopiridol in the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005526821A JP2005526821A (ja) | 2005-09-08 |
| JP2005526821A5 true JP2005526821A5 (ja) | 2006-06-08 |
| JP4429732B2 JP4429732B2 (ja) | 2010-03-10 |
Family
ID=28792053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003581783A Expired - Fee Related JP4429732B2 (ja) | 2002-04-10 | 2003-04-04 | 癌の処置におけるグリベック（ｓｔｉ５７１）とサイクリン依存性キナーゼインヒビター、とりわけフラボピリドールとの組合せ剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7888341B2 (ja) |
| EP (1) | EP1496908B1 (ja) |
| JP (1) | JP4429732B2 (ja) |
| AT (1) | ATE386528T1 (ja) |
| AU (1) | AU2003216621A1 (ja) |
| DE (1) | DE60319211T2 (ja) |
| ES (1) | ES2303585T3 (ja) |
| WO (1) | WO2003084543A1 (ja) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0209265D0 (en) * | 2002-04-23 | 2002-06-05 | Novartis Ag | Organic compounds |
| CN100467064C (zh) * | 2003-09-19 | 2009-03-11 | 诺瓦提斯公司 | 伊马替尼和米哚妥林在制备治疗胃肠道基质肿瘤药物中的应用 |
| CA2569091A1 (en) * | 2004-07-09 | 2006-01-19 | Agency For Science, Technology And Research | Modulation of gsk-3.beta. and method of treating proliferative disorders |
| BRPI0618522A2 (pt) * | 2005-11-10 | 2011-09-06 | Bayer Healthcare Ag | diaril uréia para o tratamento de hipertensão pulmonar |
| US8563595B2 (en) * | 2008-11-14 | 2013-10-22 | Board Of Regents, The University Of Texas System | Treatment of cancer with complex organic-inorganic pigment compositions |
| US20240165113A1 (en) * | 2021-04-09 | 2024-05-23 | Dna Seq 2, Inc. | Methods of treatment for leukemia |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020147197A1 (en) * | 1999-10-08 | 2002-10-10 | Newman Michael J. | Methods and compositions for enhancing pharmaceutical treatments |
| ATE426335T1 (de) | 1999-10-08 | 2009-04-15 | Taiji Biomedical Inc | Verfahren zur verbesserung der chemotherapie |
-
2003
- 2003-04-04 JP JP2003581783A patent/JP4429732B2/ja not_active Expired - Fee Related
- 2003-04-04 DE DE60319211T patent/DE60319211T2/de not_active Expired - Lifetime
- 2003-04-04 EP EP03712531A patent/EP1496908B1/en not_active Expired - Lifetime
- 2003-04-04 WO PCT/IB2003/001418 patent/WO2003084543A1/en active IP Right Grant
- 2003-04-04 AU AU2003216621A patent/AU2003216621A1/en not_active Abandoned
- 2003-04-04 AT AT03712531T patent/ATE386528T1/de not_active IP Right Cessation
- 2003-04-04 US US10/510,531 patent/US7888341B2/en not_active Expired - Fee Related
- 2003-04-04 ES ES03712531T patent/ES2303585T3/es not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chen et al. | Advances in pharmacological activities and mechanisms of glycyrrhizic acid | |
| CA2307879C (en) | Treatment of t-helper cell type 2 mediated immune diseases | |
| Luo et al. | Low-dose curcumin leads to the inhibition of tumor growth via enhancing CTL-mediated antitumor immunity | |
| JP2011037738A (ja) | 難聴又は耳鳴りの予防・治療剤 | |
| JP2005501550A5 (ja) | ||
| Liu et al. | Anti-tumor effect of polysaccharide from Hirsutella sinensis on human non-small cell lung cancer and nude mice through intrinsic mitochondrial pathway | |
| Michelsen et al. | HMPL-004 (Andrographis paniculata extract) prevents development of murine colitis by inhibiting T-cell proliferation and TH1/TH17 responses | |
| Ochayon et al. | IL-33 promotes type 1 cytokine expression via p38 MAPK in human NK cells | |
| Xiong et al. | Effects of interleukin-4 or interleukin-10 gene therapy on trinitrobenzenesulfonic acid-induced murine colitis | |
| Shen et al. | Mitochondria-dependent apoptosis of activated T lymphocytes induced by astin C, a plant cyclopeptide, for preventing murine experimental colitis | |
| US9884801B2 (en) | Compounds from antrodia camphorata, method for preparing the same and use thereof | |
| Guo et al. | Inhibition of TMEM16A by natural product silibinin: potential lead compounds for treatment of lung adenocarcinoma | |
| JP2005526821A5 (ja) | ||
| Shin et al. | Immunomodulatory and anti-inflammatory effects of Phellinus linteus mycelium | |
| Kim et al. | Sequential treatment of HPV E6 and E7-expressing TC-1 cells with bortezomib and celecoxib promotes apoptosis through p-p38 MAPK-mediated downregulation of cyclin D1 and CDK2 | |
| Li et al. | Dysfunctions, molecular mechanisms, and therapeutic strategies of regulatory T cells in rheumatoid arthritis | |
| Qu et al. | The involvement of Th1 cell differentiation in the anti-tumor effect of purified polysaccharide from Sanghuangporus vaninii in colorectal cancer via multi-omics analysis | |
| Marchalot et al. | Innate lymphoid cells in colorectal cancer | |
| Kim et al. | GLM, a novel luteolin derivative, attenuates inflammatory responses in dendritic cells: Therapeutic potential against ulcerative colitis | |
| KR101564325B1 (ko) | 지방유래줄기세포에 t항원을 도입한 adsc-t 세포의 배양액을 유효성분으로 포함하는, 염증질환의 예방 또는 치료용 조성물 | |
| JP2014237642A (ja) | 癌治療用組成物の調製のためのイカリチンの使用 | |
| KR100971374B1 (ko) | 황금 추출물을 포함하는 난청의 예방 또는 치료용 조성물 | |
| TW202002987A (zh) | 人參皂苷m1用於治療口腔癌之用途 | |
| Jang et al. | Effects of Platycodon grandiflorum on lipopolysaccharide-stimulated production of prostaglandin E2, nitric oxide, and interleukin-8 in mouse microglial BV2 cells | |
| Liao et al. | Sulforaphene Inhibits Periodontitis through Regulating Macrophage Polarization via Upregulating Dendritic Cell Immunoreceptor |